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Summary
Systemic cytotoxic chemotherapeutic treatment of malignant tumors does not fully meet its goal due to the resistance 
of present tumor cells to the applied therapy. Chemoresistance is complex and multifactorial, caused by numerous mecha-
nisms that alter drug concentration in the cell, by changes in expression of the epidermal growth factor and by activation of 
intracellular signaling pathways PI3K / Akt and MAPK. The factor of chemoresistance is also an increased level of antioxida-
tive glutathione and glutathione transferase – S enzyme and the presence of tumor stem cells that signifi cantly improve 
protection of DNA from damage. Apart from cellular factors, resistance is infl uenced by extracellular hypoxia and acidosis 
and autophagy.
Overcoming the chemoresistance is possible by using nanomechanisms for delivery of drugs to tumor cells,  autophagy 
inhibitors like antimalarials chloroquine and hydroxychloroquine and plant polyphenols.
By bett er understanding the mechanisms of chemoresistance and it’s overcoming it can be possible to achieve 
 improvement in antitumor treatment.
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POVEZIVANJE MEHANIZAMA KEMOREZISTENTNOSTI TUMORSKIH STANICA 
I SUBOPTIMALNIH SISTEMSKIH CITOTOKSIČNIH REZULTATA LIJEČENJA
Sažetak
Sustavno citotoksično kemoterapijsko liječenje zloćudnih tumora ne ispunjava u potpunosti svoj cilj zbog prisutne 
kemorezistencije tumorskih stanica na primjenjenu terapiju. Kemorezistencija je kompleksna i uzrokovana brojnim meha-
nizmima koji mijenjaju koncentraciju lijeka u stanici, promjenama u ekspresiji epidermalnog čimenika rasta i aktivacije 
unutarstaničnih signalnih puteva PI3K/Akt i MAPK. Čimbenik kemorezistencije je porast antioksidativnog enzima glutati-
ona i glutation-S transferaze te prisustvo matičnih stanica karcinoma koje značajno bolje štite DNA od oštećenja. Osim sta-
ničnih čimbenika, na rezistenciju utječe ekstracelularna hipoksija i acidoza te autofagija.
Prevladavanje kemorezistencije moguće je primjenom nanomehanizama u dostavi lijekova u tumorske stanice, inhibi-
torima autofagije antimalaricima klorokinom i hidroksiklorokinom te biljnim polifenolima.
Poznavanjem mehanizama kemorezistencije i njezinim nadilaženjem moguće je poboljšati dobrobit antitumorskog 
liječenja.




Systemic cytotoxic chemotherapeutic treat-
ment of malignant tumors does not fully meet its 
goal due to the present tumor cell chemoresistance 
to the applied therapy. Chemoresistance is com-
plex and multifactorial, caused by a number of 
mechanisms that alter cell proliferation and apop-
tosis. Mechanisms of chemoresistance include 
changes in signal pathways in the tumor cell, 
changes in transport proteins and gene polymor-
phisms that alter pharmacokinetics and drug dis-
tribution, changes in tumor microenvironment, 
and presence of tumor stem cells that eff ectively 
protect their DNA from damage. Numerous poten-
tial inhibitors of chemoresistance are being investi-
gated, and today, antimalarials and plant polyphe-
nols are available for therapeutic purposes.
Knowing and overcoming mechanisms of 
chemoresistance represents benefi t of antitumor 
treatment, with reducing the risk of relapse and 
improving overall survival.
MECHANISMS OF TUMOR CELL 
CHEMORESISTANCE
Chemoresistance
The onset of tumor is a result of alterations in 
the genome and the breakdown of normal biologi-
cal processes within the cell. Chemotherapy is one 
of the standard methods of treating many types of 
tumors, but there are still failures of treatment, 
with relapse and progression of the disease. The 
failure of chemotherapy treatment in 90% of cases 
is att ributed to the chemoresistance of tumor cells.
(1) The manifestations of resistance are divided 
into intrinsic and acquired, and both are multifac-
torial caused. (1)
Signifi cant mechanisms contributing to cel-
lular resistance include: increased expression of 
factors that reduce intracellular drug concentra-
tion, drug – tumor cell interaction alterations, and 
cellular response changes, with apoptotic path-
ways disorders and disorders in reparation of 
damaged DNA. (1)
Gene polymorphism and immune cells
Polymorphisms of genes responsible for drug 
metabolism aff ect the pharmacokinetics and dy-
namics of drugs. By identifying polymorphisms, a 
personalized approach to treatment is possible, 
with an additional increase in survival rates. It is 
especially important to identify cytochrome P450 
(CYP) and glutathione S-transferase polymor-
phisms. (2)
Signifi cant mechanism of chemoresistance 
includes immune cells, which is particularly evi-
dent in malignant melanoma. Anti-tumor immu-
nity plays an important role in activated CD4 + 
and CD8 + T cells, dendritic cells and NK cells. NK 
cells prevent the formation of metastases, espe-
cially in the liver. (3) Research fi ndings show that: 
CD4 + and CD8 + T cells, dendritic cells and NK 
cells prevent melanoma metastases in the distal 
organs. (3)
Signaling through growth factors 
and mechanisms of cell cycle control
Epidermal growth factor receptor (EGFR) acti-
vation and tyrosine kinase phosphorylation acti-
vate intracellular signaling pathways of PI3K / Akt 
and inhibit chemotherapy-induced apoptosis. Am-
plifi ed PI3K / Akt were found in 30-40% of ovarian 
cancer. Excess expression of EGFR and HER2 re-
ceptors in ovarian cancer has been associated with 
poor prognosis and lower antitumor response. (4) 
Tumor suppressor gene p53 regulates expression of 
p21 (cyclin-dependent kinase, CDK1) and leads to 
cell cycle arrest in the G1 phase. Changes in the p53 
gene are present in 50-70% of serous ovarian ade-
nocarcinoma. Since cytotoxic drugs are eff ective in 
proliferating cells, this activation leads to ineffi  cien-
cy of the drug. Changes in the p53 gene were found 
in 50 - 70% of cases of the advanced serous ovarian 
adenocarcinoma. Another important factor in the 
control of the cell cycle is the nuclear antigen Ki-67, 
its level is signifi cantly higher in the chemotherapy 
responders, and it represents a prognostic factor. 
Considering the above mentioned, numerous new 
therapeutic strategies have been explored, i.e. tar-
geted drugs acting on HER2 (trastuzumab), EGFR 
inhibitors (gefi tinib, erlotinib), anti-VEGF (bevaci-
zumab). (4)
The role of glutathione and glutathione-S 
transferase
Glutathione (GSH) plays an important role in 
many cellular processes, such as cellular diff eren-
tiation, proliferation, and apoptosis, it is involved 
in etiology and the progression of many diseases. 
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Defi ciency of GSH or reduction in the ratio of GSH 
/ glutathione disulfi de (GSSG) leads to increased 
sensitivity to oxidative stress involved in cancer 
progression. Reactive oxygen radicals (ROS) accu-
mulate during cellular damage, and more antioxi-
dants are produced compensatively. In the con-
text of tumor progression, the eff ect of antioxidant 
therapy is positive. Prooxidant therapies, includ-
ing radiation and chemotherapy, leading to the 
collapse of the oxidative system and cell death. 
Many tumors have signifi cant over-expression of 
antioxidant enzymes, especially GSH, which re-
sults in resistance of tumor cells to drugs. The 
main investigations are based on depletion of 
GSH or GSH tripeptide BSO (glutathione sulfoxi-
mine). (5) Glutathione is important in cell prolif-
eration and aff ects the activity of ribonucleotide 
reductase that limits the synthesis of DNA. Mito-
chondrial GSH dysfunction is a well-known 
mechanism for cell death, present in small – cell 
lung cancer, resistant to conventional treatments. 
Increased levels of GSH have been found in ovar-
ian, colon and liver cancer, melanoma and leuke-
mia. (5) A promising therapeutic strategy for over-
coming tumor progression and tumor chemore-
sistance is modulating the GSH antioxidant redox 
system. A series of chemically modifi ed analogs 
and precursors that copy the physiological eff ects 
of GSH (N-acetylcysteine, YM8737, NAC, S-ni-
trosoglutathion) are produced. The direct anti-tu-
mor eff ect is produced by drugs that target S-glu-
tamylation (NOV-002), combined with standard 
chemotherapeutic drugs. The other approach is 
the inhibition of Nrf2 signal pathways, which in-
creases the sensitization of chemoresistant tumors 
(brusatol). (5) Glutathione-S transferase (GST) is a 
family of phase II detoxifi cation enzymes that cat-
alyze glutathione conjugation (GSH) in a wide 
spectrum of endogenous and exogenous electro-
philic components. It is believed that GST leads to 
resistance by direct detoxifi cation or inhibition of 
the MAP kinase pathway. There is a correlation 
between GST expression and susceptibility to al-
kylating agents. Drugs that are associated with 
increased levels of GST and resistance are chlo-
rambucil, melphalan, acrolein, carmustine, ste-
roids. Etacrynic acid EA inhibits GST-α, -μ and -π 
by direct binding to the site of binding of the sub-
strate to the isoenzyme, as well as by reduction of 
its co-factor by GSH conjugation. It potentiates the 
cytotoxic eff ect of chlorambucil in cell lines of hu-
man colorectal cancer and melphalan in mice with 
SCID. (6)
Phospho-inositol - 3 kinase pathways
In response to the activation of tyrosine ki-
nase receptor (RTKs) and G-protein receptors (GP-
CRs), the PI3K / Akt and mTOR signal pathway 
promotes tumorigenesis with increased prolifera-
tion and reduced apoptosis. The PI3K pathway is 
recognized as an important anti-tumor drug resis-
tance factor, and the incidence of this resistance 
increases rapidly. Activation of PI3K is associated 
with reduced susceptibility to doxorubicin and pa-
clitaxel, where increased expression of Mcl1 anti-
apoptotic proteins contribute to resistance. The 
PI3K signal pathway may result in resistance to 
endocrine therapy, with estrogen inhibitor tamoxi-
fen, RTK inhibitors and antiangiogenic therapy 
with bevacizumab. The activity of PI3K pathway 
proved to be a predictive factor for responding to 
RTKs inhibitors and contributes to resistance to 
RTs inhibitors, including gefi tinib and trastuzum-
ab. (7) PI3K path helps in resistance to immuno-
therapy and is associated with enhanced expres-
sion of anti-apoptotic proteins, including Mcl1. 
The PI3K hyperactivity caused by the loss of PTEN 
is associated with increased PD-L1 excretion, 
which plays an important role in suppressing the 
immune system. Incomplete inhibition of PI3K 
pathway, by insuffi  ciently high drug dose, limited 
by toxicity, promotes resistance. Resistance to PI3K 
inhibitors can be derived from mechanisms pro-
moting the reactivation of PI3K signaling, mTORC1 
suppression over RTKs is interrupted and FOXO-
dependent activation of RTK expression is stimu-
lated. Activation of alternative survival pathways 
(MAPK pathway activation) and MAPK pathway 
therapeutic inhibition enhance the antitumor ac-
tivity of PI3K inhibitors. (7)
AUTOPHAGY AND CHEMORESISTANCE
Autophagy is the evolutionary retention of 
the catabolic process of the cell itself and is a re-
sponse to microcellular stressors. Current fi nd-
ings are that autophagy can act as a “guardian” 
that eliminates damaged cellular elements and 
thus protects against tumor formation, and in de-
veloped tumors acts as a protective mechanism. 
However, excessive autophagy can lead to cell 
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death, especially after treatment with chemother-
apeutics inducing apoptosis or autophagy cell 
death. Many anticancer drugs stimulate autopha-
gy by inhibiting the PI3K / Akt / mTOR signal 
pathway or by altering the genetic (epigenetic) 
phenotype of tumor cells. Just as autophagy has 
the potential to induce cell death or promote sur-
vival, there is more and more evidence that au-
tophagy has a paradoxical role after antitumor 
therapy, when it can result in increased or de-
creased antitumor activity. During chemotherapy, 
it is activated as a protective mechanism and au-
tophagy inhibition can, in this case, lead to the 
susceptibility of proliferating resistant cells. On 
the other hand, autophagy can lead to cell death. 
Antitumor drugs appear to induce diff erent ef-
fects of autophagy in diff erent tumors. Studies 
have shown that tumor resistance to radiotherapy, 
chemotherapy, and targeted therapy can be fur-
ther enhanced by autophagy mechanisms, and 
therefore autophagy inhibition may enhance che-
motherapy toxicity, especially if there is a combi-
nation of several diff erent drugs. (8) The only au-
tophagy inhibitors whose effi  cacy and safety has 
been demonstrated in vivo, chloroquine (CQ) and 
its hydroxychloroquine derivative (HCQ), block 
auto-phagosomal fusion and degradation. Both 
drugs were investigated in preclinical and clinical 
studies. There is evidence that epirubicin could in-
duce autophagy in MCF-7 tumor cells, resulting in 
the protection of these cells from apoptosis in-
duced by epirubicin. Autophagy is also consid-
ered to be a key mechanism in anti-estrogen resis-
tance. (8) Studies have shown that inhibition of 
autophagy leads to an anti-cancer eff ect of chemo-
therapy or targeted therapy in colorectal cancer. 
Recently, it has been shown that MAPK14 / p38 
protein is involved in resistance to carcinoma cells 
at 5-FU and irinotecan, which acts as a trigger to 
autophagy to protect tumor cells from the cyto-
toxic activity. The combination of inhibition of au-
tophagy and chemotherapy or targeted therapy 
promises a lot in the treatment of HCC. Autopha-
gy is activated in HCC after treatment with oxali-
platin, and autophagy suppression increases the 
cytotoxic eff ect of oxaliplatin. Combination of au-
tophagy inhibition and bevacizumab has been 
shown to signifi cantly reduce tumor growth. Also, 
a combination of sorafenib and CQ can lead to in-
creased death of tumor cells. (8) EGFR-TK inhibi-
tors are widely used in patients with non-squa-
mous lung cancer. The effi  cacy of these drugs is 
limited due to naturally acquired resistance. Au-
tophagy can be induced by erlotinib or gefi tinib, 
EGFR-TKIs. Furthermore, CQ has proven to be a 
drug that can lead to improved sensitivity to che-
motherapy and radiation in several preclinical 
models. CQ not only potentiates topotecan cyto-
toxicity, but may also enhance the eff ect of the 
PI3K / mTOR inhibitor NVP-BEZ235 on induction 
of apoptosis, inhibition of colonization, and sup-
pression of xenograft on mice. Stage I study in pa-
tients with advanced nonsquamous lung cancer, 
who demonstrated the prior clinical benefi t of 
EGFR-TKIs, showed that HCQ with or without er-
lotinib is safe and Phase II is recommended, in 
which the erlotinib dose would be 150 mg daily 
and HCQ 1000 mg daily. (8) Several studies have 
shown that autophagy acts as a survival factor 
and leads to chemoresistance in prostate and kid-
ney cancer. Activation of autophagy protects tu-
mor cells from cell death, while inhibition of au-
tophagy suppresses PC-3, a growth factor in pros-
tate cancer cells in vivo. Administration of high 
doses of interleukin 2 (HDIL-2) has shown a par-
tial or complete response to therapy in some pa-
tients with metastatic kidney cancer. However, 
treatment (HDIL-2) is often limited by side - ef-
fects due to cytokine-induced systemic autophagy 
syndrome. The combination of IL-2 and CQ has 
been shown to enhance antitumor activity, with 
reduced toxicity, compared to IL-2 alone, which is 
a new area of research and strategy to improve 
HDIL-2 immunotherapy in patients with kidney 
cancer. Autophagy could be one of the factors in 
resistance to the drugs of patients with clear cell 
ovarian cancer. The NAC-1 protein can mediate 
cisplatin resistance by activating autophagy. In 
this case, inhibition of autophagy would also lead 
to necrosis and cell tumor calming. A combination 
of sorafenib and HCQ for FIGO III and IV ovarian 
carcinoma was investigated. In addition to anti-
malarials, the ablation of autologous regulator 
genes Beclin 1, ATG 5, ATG6, ATG7, and ATG12 
has been shown to result in increased sensitivity 
to chemotherapeutics.
Various autophagy inhibitors block the pro-
cess at diff erent levels. Chloroquine and its deriv-
atives are currently the only autophagy inhibitors 
available for treatment of patients. In the studies, 
HCQ is often used in combination with chemo-
therapy, radiation therapy, targeted therapy or 
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immunotherapy. These two drugs can inhibit au-
tophagy-mediated survival mechanisms and lead 
to antitumor eff ect enhancement. (8)
ADAPTIVE RESISTANCE 
IN BREAST CANCER
The appearance of recurrence and metastasis 
of the primary tumor after antitumor therapy is a 
challenge to successful treatment strategies. Ra-
diotherapy is a powerful tool to control tumor 
growth, however, the tumor develops an adaptive 
response to radiotherapy and becomes more resis-
tant and aggressive. HER2 is a marker for the re-
sistance of cancer stem cells (CSC) to radiothera-
py. Clinical data show that patients suff ering from 
breast cancer with increased HER2 expression live 
by one third shorter than HER2 negative tumors. 
Tumor radiosensitivity creates a major challenge 
for the treatment of cancer, and CSCs have proved 
to be more resistant than non-CSC cells. CSC is be-
lieved to be responsible for the failure of therapy 
and tumor relapses. Repopulation of cancer cells 
after treatment has long been considered a cause 
of failure of treatment. (9) One of the main charac-
teristics of the stem cells as well as CSC is that they 
can signifi cantly bett er protect DNA from harmful 
eff ects than non-stem cells. Radiation causes cell 
death by causing diffi  cult repair of DNA. More 
evidence supports the link between radiosensitiv-
ity and signaling of DNA damage. Therapeutic 
ionizing radiation (IR) leads to DNA damage and 
oxidative stress which activates specifi c signal 
pathways in the irradiated cells. Depending on 
the level of DNA damage, either survival or apop-
totic mechanisms will be triggered. Philips et al. 
have shown that the NOtch signal pathway acti-
vates in CSC of breast cancer after exposure to ra-
diation via PI3K, leading to an increased number 
of CSC. (9) Enhanced HER2 expression exists in 
15-30% of patients and is associated with more ag-
gressive tumor growth, increased recurrence risk, 
and resistance to therapy. HER2 is a proto-onco-
gene located on the long arm of chromosome 17 
and encodes the expression of the HER2 glycopro-
tein receptor on the tumor cell membrane. Discov-
ery of epidermal growth factor receptor (EGFR) 
and later anti-HER2 monoclonal antibodies to 
trastuzumab represents a signifi cant advance in 
the treatment of breast cancer. Data suggests that 
HER2 is a marker for radiosensitive CSC. Thus, 
HER2 negative cancer can “wake up” the mute 
HER2 expression after radiation, which explains 
the potential benefi t of anti-HER2 treatment in 
primary HER2 negative breast cancer. Breast can-
cer cells that have poor HER2 expression before 
radiation may become radioresistant due to in-
creased expression of HER2 and/or Her2-NF-kB-
Her2 loop, activated after ionizing radiation. (9)
OVERCOMING MULTIPLE DRUG 
RESISTANCE
Nanomechanisms of drug delivery to tumor cells
Potential Multi-Drug Resistance (MDR) fac-
tors include increased drug detoxifi cation, re-
duced drug intake, increased intracellular levels 
of nucleophiles, enhanced drug repair of drug-in-
duced cell damage, overexpression of drug trans-
porter (P-glycoprotein / P-gp, MRP1, and 2-multi-
drug resistance-associated proteins, BCRP -breast 
cancer resistance protein). Current nanoparticles 
such as polymeric nanoparticles, liposomes and 
mycelium are innovative platforms for the treat-
ment of tumor cell multiresistance. Nanomecha-
nisms have the potential to improve the therapeu-
tic drug index. (10) Resistance to drugs is a result 
of a reduction in the eff ective drug concentration 
in the cell. Numerous resistance mechanisms are 
known: increased expression of the effl  ux pumps 
(P-gp, MRP1, BCRP), drug elimination and drug 
detoxifi cation, drug sequestration within lipo-
somes or endosomes, reduced drug intake due to 
altered carriers, inactivation of the drug via gluta-
thione-mediated reductions, drug-binding sites, 
increased DNA repair capacity through topoisom-
erase II, decreased apoptosis, hypoxia-regulated 
expression of MDR-related genes such as ABC-
transporter, Bcl2 family of genes, glutathione, 
 metalloproteins etc. (by activation of HiF1 tran-
scription factors). (7) Recurrent metastatic ovarian 
cancer is usually resistant to multiple chemothera-
peutics. The hypothesis of resistance is based on 
the presence of stem cells (cancer stem cells / CSC) 
that can overcome the eff ect of chemotherapy and 
metastasize. ABCB1 is a cell transporter that is en-
hanced in a paclitaxel-resistant cell line. (10) Fork-
head box (Fox) transcription factors are proteins 
that play a key role in the regulation of numerous 
biological binding processes for specifi c DNA se-
quences. The most important are FxO3a that is a 
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tumor suppressor, FoxM1 that is an oncogene and 
FoxA that has the ability to initiate transcription 
genes. Oncogene myc is negatively regulated by 
FoxO3a, which can play a key role in controlling 
cellular metabolism during initiation and cancer 
progression. (11) Decreased intracellular accumu-
lation of drugs in resistant leukemia cells is not 
only MDR effl  ux-mediated but also by reduced 
cellular confl uence. Reduced drug accumulation 
in resistant cells is explained by the possibility of 
expulsion. Resistant cells have an overexpression 
of ABCB1 conveyor which expel the medicament 
from the target cells and targeted competitive in-
hibitors have produced that bind to the transport-
er, with at least the same affi  nity as a medicament. 
However, the intracellular drug concentration is 
the balance between the drug accumulation due to 
the intake and its clearance by the effl  ux. The cur-
rent model assumes that drug intake is constant, 
but resistance may be a consequence of reduced 
endocytosis / cytotoxic drug infl ammation. (12)
Tumor microenvironment and strategies 
to overcome chemoresistance
Hypoxia (partial oxygen pressure lower than 
10 mmHg) and acidity with low levels of nutrients 
are key factors of the tumor microenvironment. 
Acidity causes activation of proteases, rising in 
permeability of the vasculature, with the increase 
of interstitial pressure and the rise of the P-gp lev-
el. Hypoxia activates the HIF-1 transcriptional fac-
tor that induces resistance and metastasis. Acidity 
extracellularly reduces doxorubicin and mitoxan-
trone cellular infl ux, while hypoxia regulates an-
giogenic VEGF, placental growth factor (PGF), 
TGFα, IL-8 and hepatocyte growth factor (HGF). 
(13) The strategies for overcoming the MDR by ex-
pression of genes encoding P-go transporter, 
MDR-1 or Survivin RNA interference (RNAi) or 
RNA (small interfering RNA) are studied. In the 
studies, chemically synthesized siRNAs that re-
duce MDR1 / P-gp mRNA and protein expression 
and anti-ABC transporter shRNA have a high po-
tential for MDR. Monoclonal antibodies to P-gp 
(Mabs) have the potential of targeting P-gp and 
killing MDR tumor cells. (13) Then there is a de-
velopment of antitumor drugs that do not sub-
strate P-gp: taxanes are not recognized by P-go 
transporter, ABC transporter inhibitors, nano-
somes - diff erent types of nanoparticles (polymer-
ic, solid lipid, magnetic nanoparticles, mesopore 
silicones, liposomes, mycelial). Nanosilicants 
overcome the challenge of bioavailability and 
ABC-mediated drug effl  ux. (13)
Chemosensitization and radiosensitization 
of tumors with plant polyphenols
Many plant polyphenols: genistein, piperine, 
curcumin, resveratrol, silymarin, caff eic acid phe-
nethyl ester, fl avopiridol, hemodynes, green tea 
polyphenols, oleandrine, ursolic acid, and betu-
linic acid have been investigated in tumor sensiti-
zation to applied chemo and radiotherapy. Re-
search has shown their role in inhibiting cellular 
pathways that lead to resistance and are also pro-
tective in therapy-induced toxicity. Numerous 
photochemical agents are associated with block-
ade of initiation and tumor development by acting 
on the pathways of MAP kinase and PI-3K. The 
activation of the NF-κB transcription factor by 
chemotherapy and radiation can lead to treat-
ment-induced resistance, inhibits chemotherapy-
induced apoptosis. Expression of COX-2-enzyme 
is associated with poor treatment outcome and in 
many studies investigated selective COX-2 inhibi-
tion. Plant polyphenol genistein (soy) by inhibi-
tion of NF-κB can increase the eff ectiveness of che-
motherapy and radiation, eff ects proven in pan-
creatic cancer cells, lungs, prostate, melanoma, 
and leukemia. Resveratrol polyphenol from 
grapes has in more studies demonstrated the ef-
fect of suppressing proliferation of lymphoid and 
myeloid tumors, bowel cancer, breast cancer, 
prostate, pancreas, ovarian, cervix. Curcumin 
(Curcuma longa) expresses the expression of NF-
κB target genes (COX-2, iNOS, MMP-9, UPA, cy-
clin D1, EGFR) and suppresses the activation of 
NF-κB. It potentiates cytotoxic eff ects of doxorubi-
cin, 5-FU, and paclitaxel in prostate cancer cells. It 
modulates the MDR gene activity and thereby 
suppresses the drug effl  ux via P-gp, leading to 
chemosensitization. Green tea polyphenols (caf-
feine, EGCG, and fl avonoids) inhibit the effl  ux of 
doxorubicin from Ehrlich ascites cancer cells. 
EGCG inhibits activation of the NF-κB in the pros-
tate, epidermoid, head and neck cancer cells and 
some breast cancer, and lung cancer. The amino 
acid teanine (glutamate-transporter inhibitor) has 
a synergistic eff ect with doxorubicin in the ovari-
an sarcoma and increases the activity of cisplatin, 
irinotecan, CP-11. The oral administration of te-
anine from green tea has the same eff ect. Flavo-
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piridol potentiates the eff ect of chemotherapy on 
breast and stomach cancer. It also increases the 
cytotoxic eff ect of paclitaxel, cytarabine, topote-
can, doxorubicin, and etoposide, only when ad-
ministered after treatment. The mechanism of ac-
tion may include inhibition of NF-κB and inhibi-
tion of NF-κB gene transcription. Silymarin on 
animal models protects against cardiotoxicity of 
an anthracycline, possibly by stabilizing the cell 
membrane or by capturing free radicals. In addi-
tion to synergistic eff ects with oncological thera-
py, polyphenols protect normal cells from chemo-
therapy / radiotherapy-induced toxicity. Curcum-
in has been shown to be protective in renal, cardiac 
and GI system damage caused by doxorubicin, by 
suppressing oxidative stress. Ginger reduces nau-
sea caused by radiation and chemotherapy. (14)
CONCLUSION
Many cell mechanisms build resistance of tu-
mor cell to antineoplastic treatment. That is prob-
ably the key to suboptimal results in the cytotoxic 
treatment of cancer. Thus, many natural products 
and parts of everyday nutrition, especially healthy 
nutritive regimens, are well known for their anti-
cancer activity. This anticancer activity is in much 
no less than prevention or correction/disruption 
of cancer cell developed chemoresistance. All of 
the mentioned is to date recognized and described 
through the majority of the most frequent solid tu-
mors and hemoblastoses, which gives an insight 
of how complex and dynamic the interaction of 
tumor cell and antitumor treatment, as well as any 
manipulation of it, can be. It also gives a hope that 
not everything depends on the nonselective, cyto-
toxic eff ect of chemo and radiotherapy used, but 
that there are ways of tricking cells mechanisms in 
developing their defense against treatment, and 
somewhat of it, we already witness, through de-
velopment and usage of targeted therapies.
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